Eton Pharmaceuticals, Inc. (ETON)
| Market Cap | 112.36M |
| Revenue (ttm) | 33.48M |
| Net Income (ttm) | 2.23M |
| Shares Out | 25.65M |
| EPS (ttm) | 0.10 |
| PE Ratio | 43.80 |
| Forward PE | 85.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 128,483 |
| Open | 4.60 |
| Previous Close | 4.60 |
| Day's Range | 4.26 - 4.69 |
| 52-Week Range | 2.42 - 5.81 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+128.31%) |
| Earnings Date | Nov 9, 2023 |
About ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning. It also provides Zeneo hydroco... [Read more]
Financial Performance
In 2022, ETON's revenue was $22.89 million, a decrease of -1.89% compared to the previous year's $23.33 million. Losses were -$9.02 million, 361.4% more than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ETON stock is "Strong Buy" and the 12-month stock price forecast is $10.0.
News
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
DEER PARK, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to add...
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04, 2023...
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
DEER PARK, Ill., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare disease...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETON
NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ: ETON). Such investors are advis...
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
DEER PARK, Ill., June 28, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...
Eton Pharmaceuticals Reports First Quarter 2023 Financial Results
DEER PARK, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tre...
Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Product is now available exclusively through Optime Care -- DEER PARK, Ill., May 10, 2023 (GLOBE...
Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
DEER PARK, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the ...
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseas...
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
-- Product previously granted orphan drug designation for methanol poisoning ---- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmace...
Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results
DEER PARK, Ill., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare disease...
Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatme...
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
-- Expected to be accretive to 2023 earnings -- DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company ...
Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
DEER PARK, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...
Why Eton Pharmaceuticals Stock Is Moving Higher
Eton Pharmaceuticals Inc (NASDAQ: ETON) shares are trading higher Monday after the company announced FDA approval of ZONISADE. ZONISADE was included in Eton's multi-product partnership with Azurity Ph...
Eton's stock gains 16% after announcing FDA approval of epilepsy drug
Shares of Eton Pharmaceuticals Inc. ETON, +3.33% jumped 16.5% in premarket trading on Monday after the company said the Food and Drug Administration approved Zonisade, a seizure treatment for adults a...
Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)
DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare disease...
Eton Pharma Shares Tick Higher After Offloading Hospital Products
Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories Ltd (NYSE: RDY), for $50 million. "The sale of our hospi...
Eton Pharmaceuticals Announces Sale of Hospital Products
DEER PARK, Ill., June 24, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...